Full Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Key Points
- Dr Reddy's Laboratories Ltd (RDY) launched seven new generic products across markets in the quarter, expanding their European product portfolio.
- The company reported a 37% year-over-year growth in their European business, driven by acquisition-led growth.
- Dr Reddy's Laboratories Ltd (RDY) is focused on advancing its differentiated pipeline program, including semaglutide, which has received approval in Canada.
- The company plans to maintain a double-digit growth trajectory in North America, excluding the impact of semaglutide.
- Dr Reddy's Laboratories Ltd (RDY) is actively pursuing value-accretive inorganic opportunities to support sustainable long-term stakeholder value.
- The European business posted a revenue decline of 3% for the quarter, attributed to challenges in the generics market.
- The PSAI business reported a 10% year-over-year revenue decline due to lower API volume uptake.
- There was a significant $50 million short stock adjustment for the product Revlimid, attributed to planning issues at the customer end.
- The biosimilar business has not yet reached breakeven, with expectations for profitability hinging on future product launches.
- The US market has experienced price erosion, impacting revenue growth despite new product launches.
'-
(audio in progress) over FY26, reflecting our continued focus on strengthening our domestic market presence. Our European business, which includes our acquired Consumer Health business in nicotine replacement therapy, posted revenue of [$136 million] for the quarter, a decline of 3% on a year-on-year basis as well as sequentially and [EUR 542 million] for FY26, reflecting an acquisition-led growth of 37% year-over-year. The decline this quarter was primarily on account of (inaudible) generics.
During the quarter, we launched seven new generic products across markets, taking the full year total to 38, further expanding our European product portfolio. Our PSAI business reported revenue of USD1 million in Q4 FY26, resulting in a decline of 10% year over year and a growth of 10% sequentially. The decline was primarily on account of lower API volume uptick during the quarter. During the quarter, we filed 48 (inaudible) taking the total number of filings to 128 for the year.
Looking ahead, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
